Physostigmine, a centrally-acting cholinesterase inhibitor, has been shown to have potential as a treatment for primary degenerative dementia. In an experiment to test its effects, i.v. physostigmine caused the onset of unifocal premature contractions and runs of bigeminy in an 85-year-old man.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of Clinical Psychiatry|
|State||Published - Dec 1 1985|